Menopause-related Vasomotor Symptoms
📧 Sign up to get email alerts when something new happens for Menopause-related Vasomotor Symptoms.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-10-15FDA Approved: ESTROGENS, CONJUGATED — Original Application (Ingenus Pharmaceuticals, LLC)
FDA approved a generic version of conjugated estrogens under an original ANDA from Ingenus Pharmaceuticals.
-
FDA approval · 2024-07-12FDA Approved: ESTRADIOL — Original Application (Amneal Pharmaceuticals NY LLC)
The FDA approved Amneal Pharmaceuticals NY LLC's Original Application for Estradiol transdermal, a generic estradiol product. The approval c…
-
CLINICAL_TRIALS trial_result · 2023-10-26Clinical Trial Update: FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms [Phase 2]
Phase 2 trial update evaluating FP-101 vs placebo for vasomotor symptoms associated with menopause has completed.
-
CLINICAL_TRIALS trial_result · 2021-08-05Clinical Trial Update: Post Marketing Surveillance To Observe Safety And Efficacy Of Duavive
Post-marketing surveillance trial to observe safety and efficacy of Duavive in severe vasomotor symptoms of menopause has completed with res…
-
CLINICAL_TRIALS trial_result · 2013-12-11Clinical Trial Update: Dehydroepiandrosterone (DHEA) + Acolbifene Against Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women [Phase 3]
Phase 3 trial evaluating dehydroepiandrosterone (DHEA) plus acolbifene for vasomotor symptoms (hot flashes) in postmenopausal women has comp…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS safety_alert · 2013-11-19Clinical Trial Update: Angeliq Regulatory Post Marketing Surveillance
Bayer's Angeliq post-marketing surveillance update summarizes ongoing regulatory safety monitoring in postmenopausal women, including osteop…
-
CLINICAL_TRIALS trial_result · 2012-03-26Clinical Trial Update: A Study to Evaluate the Effects of RAD1901 in the Treatment of Vasomotor Symptoms in Postmenopausal Women [Phase 2]
A Phase 2 trial evaluating RAD1901 for vasomotor symptoms (hot flashes) in postmenopausal women has completed with results posted in 2012.
-
FDA approval · 2011-10-28FDA Approved: CONJUGATED ESTROGENS — Supplemental Application (Prasco Laboratories)
FDA has approved a supplemental NDA for Conjugated Estrogens (Estrogens, Conjugated) from Prasco Laboratories.
-
CLINICAL_TRIALS trial_result · 2011-06-08Clinical Trial Update: Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women [Phase 2]
Phase 2 study of gabapentin extended-release for vasomotor symptoms in postmenopausal women has completed.
-
FDA approval · 2008-10-30FDA Approved: EVAMIST — Supplemental Application (Padagis US LLC)
The FDA approved a supplemental application for EVAMIST, a transdermal estradiol product, under Padagis US LLC.
-
FDA label_change · 2006-07-26FDA Approved: PREMARIN — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)
FDA approved a supplemental application for PREMARIN (conjugated estrogens), resulting in changes to the product labeling.